Cantor Fitzgerald reiterated their buy rating on shares of Mesoblast limited (NASDAQ:MESO) in a research note issued to investors on Wednesday morning.

“Accelerating Chronic Heart Failure (CHF). Mesoblast recently outlined its plans to seek a potential accelerated approval pathway for its MPC-150-IM product in patients with advanced cardiac heart failure. Based on the significant unmet need and serious complications of the disease, the company believes its 159-patient Phase 2b study with end-stage (Class IV) CHF patients that require left ventricular device (LVAD) assistance could support an accelerated approval. Completion of enrollment is imminent, and top-line data from the study are expected in 1Q18. The primary endpoint of the study will assess the number of times patients are able to undergo weaning off LVAD assistance. Enrolling in Advanced CHF. Mesoblast is also conducting a large 600-patient Phase 3 study in advanced (Class II/III) CHF patients that could serve as a confirmatory study and has enrolled over 400 patients so far. This study will assess recurrent, non-fatal, HF-related major adverse cardiac events between MPC-treated and sham-treated patients. Data are expected to be released in 2019. Attractive Markets. We estimate a large, multi-billion-dollar market for Mesoblast’s cell portfolio (combined royalties of ~$6 billion) when it reaches peak market penetration.”,” the firm’s analyst commented.

Other equities research analysts have also issued research reports about the stock. Maxim Group set a $14.00 price objective on shares of Mesoblast limited and gave the stock a buy rating in a report on Thursday, May 25th. Zacks Investment Research raised shares of Mesoblast limited from a sell rating to a buy rating and set a $10.00 price objective on the stock in a report on Tuesday, May 23rd. Credit Suisse Group set a $11.00 price objective on shares of Mesoblast limited and gave the stock a hold rating in a report on Tuesday, July 18th. Finally, BidaskClub lowered shares of Mesoblast limited from a hold rating to a sell rating in a report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $12.70.

Shares of Mesoblast limited (MESO) opened at 6.24 on Wednesday. Mesoblast limited has a one year low of $4.01 and a one year high of $12.50. The stock has a 50 day moving average of $7.20 and a 200-day moving average of $8.23. The stock’s market capitalization is $496.35 million.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/31/mesoblast-limiteds-meso-buy-rating-reaffirmed-at-cantor-fitzgerald.html.

A hedge fund recently raised its stake in Mesoblast limited stock. Princeton Capital Management Inc. raised its position in shares of Mesoblast limited (NASDAQ:MESO) by 15.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 155,700 shares of the company’s stock after buying an additional 20,945 shares during the period. Princeton Capital Management Inc. owned approximately 0.20% of Mesoblast limited worth $1,398,000 as of its most recent filing with the SEC. 2.95% of the stock is currently owned by institutional investors and hedge funds.

Mesoblast limited Company Profile

Receive News & Stock Ratings for Mesoblast limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast limited and related stocks with our FREE daily email newsletter.